Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Because Leqembi is a Part B drug, not a more common Part D drug, many Medicare patients will owe 20 percent of the cost out-of-pocket. That adds up to more than $5,000 annually.

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...